Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 26, Issue 30, 2008, Pages 4952-4957

  Wiernik, Peter H ^a   Lossos, Izidore S ^a   Tuscano, Joseph M ^a   Justice, Glen ^a   Vose, Julie M ^a   Cole, Craig E ^a   Lam, Wendy ^a   McBride, Kyle ^a   Wride, Kenton ^a   Pietronigro, Dennis ^a   Takeshita, Kenichi ^a   Ervin Haynes, Annette ^a   Zeldis, Jerome B ^a   Habermann, Thomas M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; PREDNISONE; RITUXIMAB; SGN 40; TOSITUMOMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; BILIRUBIN BLOOD LEVEL; CANCER REGRESSION; CANCER RELAPSE; CAUDA EQUINA SYNDROME; CELLULITIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HEART FAILURE; HEART INFARCTION; HEMATURIA; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; INFECTION; INSOMNIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; LYMPHOMA; MALAISE; MALE; MANTLE CELL LYMPHOMA; MENTAL HEALTH; MOEBIUS SYNDROME; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OSTEOMYELITIS; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPINAL HEMATOMA; SWEATING; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; URINARY FREQUENCY; VEIN THROMBOSIS; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; HEMATOLOGIC DISEASE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; REMISSION; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; REMISSION INDUCTION; THALIDOMIDE;

EID: 54449095901     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.3429     Document Type: Article

References (25)

1. Coiffier B, Lepage E, Briére J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
2. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005
3. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
4. Morrison VA, Weller EA, Habermann TM, et al: Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. J Clin Oncol 25:443s, 2007 (suppl; abstr 8011)
5. Witzig TE: Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23:6409-6414, 2005
6. Philip T, Armitage JO, Spitzer G, et al: Highdose therapy and autologous bone marrow transplantation after failure of conventional therapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
7. Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322, 2004
8. Chang DH, Liu N, Klimek V, et al: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 108:618-621, 2006
9. Gandhi AK, Kang J, Naziruddin S, et al: Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30: 849-858, 2006
10. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
11. Verhelle D, Corral LG, Wong K, et al: Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67:746-755, 2007
12. Galustian C, Klaschka, DC, Meyer B, et al: Lenalidomide (Revlimid, CC-5013) and Actimid (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: Implications for anti-tumor activity in vivo. Proc Am Assoc Cancer Res 47:754a, 2006 (abstr 4882)
13. Lentzsch S, LeBlanc R, Podar K, et al: Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17:41-44, 2003
14. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
15. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
16. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
17. Fosså A, Santoro A, Hiddemann W, et al: Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 17:3786-3792, 1999
18. Coiffier B, Haioun N, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
19. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11:5984-5992, 2005
20. Bartlett JB, Wu L, Adams M, et al: Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. J Clin Oncol 25:123s, 2007 (suppl; abstr 3023)
21. Wu L, Adams M, Schafer P, et al: Lenalidomide strongly enhances natural killer cell and monocyte mediated antibody-dependent cellular cytotoxicity of rituximab treated CD20+ve cancer cells in vitro. Haematologica 92:113, 2007 (suppl 1; abstr 0314)
22. Wang M, Fayad L, Hagemeister F, et al: A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 25:448s, 2007 (suppl; abstr 8030)
23. Witzig T, Vose JM, Moore TD, et al: Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood 110:1147, 2007 (abstr 2560)
24. Fanale MA, Younes A: Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67:333-350, 2007
25. Barr P, Fisher R, Friedberg J: The role of bortezomib in the treatment of lymphoma. Cancer Invest 25:766-775, 2007